Abstract

BackgroundAcute myeloid leukemia (AML) with the t(8;21)(q22;q22) chromosomal translocation is among the most common subtypes of AML and produces the AML1-ETO (RUNX1-ETO, RUNX1-RUNX1T1) oncogenic fusion gene. AML1-ETO functions as an aberrant transcription factor which plays a key role in blocking normal hematopoiesis. Thus, the expression of AML1-ETO is critical to t(8;21) AML leukemogenesis and maintenance. Post-transcriptional regulation of gene expression is often mediated through interactions between trans-factors and cis-elements within transcript 3′-untranslated regions (UTR). AML1-ETO uses the 3′UTR of the ETO gene, which is not normally expressed in hematopoietic cells. Therefore, the mechanisms regulating AML1-ETO expression via the 3’UTR are attractive therapeutic targets.MethodsWe used RNA-sequencing of t(8;21) patients and cell lines to examine the 3′UTR isoforms used by AML1-ETO transcripts. Using luciferase assay approaches, we test the relative contribution of 3′UTR cis elements to AML1-ETO expression. We further use let-7b microRNA mimics and anti-let-7b sponges for functional studies of t(8;21) AML cell lines.ResultsIn this study, we examine the regulation of AML1-ETO via the 3’UTR. We demonstrate that AML1-ETO transcripts primarily use a 3.7 kb isoform of the ETO 3′UTR in both t(8;21) patients and cell lines. We identify a negative regulatory element within the AML1-ETO 3′UTR. We further demonstrate that the let-7b microRNA directly represses AML1-ETO through this site. Finally, we find that let-7b inhibits the proliferation of t(8;21) AML cell lines, rescues expression of AML1-ETO target genes, and promotes differentiation.ConclusionsAML1-ETO is post-transcriptionally regulated by let-7b, which contributes to the leukemic phenotype of t(8;21) AML and may be important for t(8;21) leukemogenesis and maintenance.

Highlights

  • The t(8;21)(q22;q22) translocation is among the most common chromosomal abnormalities in Acute myeloid leukemia (AML) [1]

  • Using a luciferase assay approach to identify regulatory elements within the 3.7 kb AML1-ETO 3′untranslated regions (UTR), we found a fragment of the AML1-ETO 3′UTR between 2.8 and 3.4 kb which was negatively regulated, increased expression upon inhibition of miRNA biogenesis, and contained a putative miRNA let-7 target site

  • A validated poly(A) site is located at 3.7 kb, suggesting that AML1-ETO transcripts terminate at this proximal poly(A) site resulting in the observed shorter 3′UTR in patients

Read more

Summary

Introduction

The t(8;21)(q22;q22) translocation is among the most common chromosomal abnormalities in AML [1]. ETO (RUNX1T1) is not normally expressed in hematopoietic progenitor cells [8,9,10], does not have DNA binding activity [11], and interacts with transcriptional co-repressors and co-activators [6, 11,12,13,14,15,16]. The AML1-ETO fusion transcription factor impairs normal AML1-mediated myeloid differentiation through the transcriptional dysregulation of critical hematopoietic genes [6, 17,18,19,20,21,22,23,24,25], additional mutations are required for leukemogenesis [26, 27]. The mechanisms regulating AML1-ETO expression via the 3’UTR are attractive thera‐ peutic targets

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call